Amferia’s first product for human care is our antibacterial peptide wound dressing. Amferia is developing several dressing formats that feature our patented hydrogel-peptide, starting with a non-adhesive dressing for dry to low exuding wounds, while pipeline products cater to the numerous needs within wound care while keeping the antibacterial property intact.
When applied as a solid wound dressing pad, Amferia’s antibacterial peptide hydrogel can reduce bacteria on the dressing by upto 99.99%, providing an effective, clean environment for wound recovery.
The global advanced wound care market is estimated to be 7 billion USD today and growing at a rate of 5% annually.
Amferia’s proprietary peptide-hydrogel acts as the contact layer to the wound, for providing a moist environment conducive for wound healing while protecting the wound from contamination.
Today, Amferia has recived FDA De Novo classification for the first wound dressing comprising antiabcterial peptides and has ongoing clinical investigations in US.
The global advanced wound care market is estimated to be 7 billion USD today and growing at a rate of 5% annually.
